tiprankstipranks
Cantargia AB (SE:CANTA)
:CANTA
Sweden Market
CANTA
Cantargia AB
RESEARCH TOOLSreports
Want to see SE:CANTA full AI Analyst Report?

Cantargia AB (CANTA) Stock News & Sentiment

3 Followers
Cantargia: Buy Rating Reiterated on Strategic Pipeline Progress and Unchanged $14 Price Target
Premium
Ratings
Cantargia: Buy Rating Reiterated on Strategic Pipeline Progress and Unchanged $14 Price Target
2d ago
Cantargia AGM Backs Equity Incentives and Expands Capital Raising Mandate
Premium
Company Announcements
Cantargia AGM Backs Equity Incentives and Expands Capital Raising Mandate
3d ago
Cantargia Highlights Pipeline Progress in Q1 2026 Interim Report
Premium
Company Announcements
Cantargia Highlights Pipeline Progress in Q1 2026 Interim Report
6d ago
Cantargia to Present Q1 2026 Interim Results in Audiocast and Teleconference
Premium
Company Announcements
Cantargia to Present Q1 2026 Interim Results in Audiocast and Teleconference
19d ago
Cantargia Reiterated as Buy on Nadunolimab’s Strong Early Data and Pipeline Progress; Price Target Maintained at SEK14
Premium
Ratings
Cantargia Reiterated as Buy on Nadunolimab’s Strong Early Data and Pipeline Progress; Price Target Maintained at SEK14
27d ago
Cantargia Reports Promising Early Remissions with Nadunolimab in High-Risk MDS and AML Trial
Premium
Company Announcements
Cantargia Reports Promising Early Remissions with Nadunolimab in High-Risk MDS and AML Trial
28d ago
Cantargia Showcases New Nadunolimab Trial in Hard-to-Treat Colorectal Cancer at AACR 2026
Premium
Company Announcements
Cantargia Showcases New Nadunolimab Trial in Hard-to-Treat Colorectal Cancer at AACR 2026
1M ago
More SE:CANTA News >

CANTA News on the Web

Cantargia Reiterated as Buy on Nadunolimab’s Strong Early Data and Pipeline Progress; Price Target Maintained at SEK14
TipRanks News
Neutral
Cantargia convenes 2026 AGM with focus on continuity in board
TipRanks News
Neutral
Cantargia: Solid Cash Runway and Expanding Nadunolimab Pipeline Support Buy Rating and Long-Term Upside
TipRanks News
Bullish
Cantargia Sets Date for 2025 Annual Results and Investor Presentation
TipRanks News
Bullish
Cantargia to Engage Investors at Leerink Global Healthcare Conference
TipRanks News
Bullish
Expanding Nadunolimab’s Oncology Footprint: Low-Cost MSS-CRC Study De-Risks Pivotal Pancreatic Program and Supports Buy Rating on Cantargia AB
TipRanks News
Bullish
Cantargia Begins US Trial of Nadunolimab Combo in Hard-to-Treat Colorectal Cancer
TipRanks News
Bullish
Cantargia AB’s Promising Interim Report for Early 2025
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
SE:CANTA
Sector Average
Media Buzz
This Week1 articles
Weekly Average0.25 articles
News Sentiment
This Week100%
Sector Average78%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is SE:CANTA’s Media Buzz Sentiment?
1 articles about SE:CANTA were published this week. In an average week, 0.25 articles are published.
    What is SE:CANTA’s weekly average amount of articles?
    In an average week, 0.25 articles about SE:CANTA are published.
      What is SE:CANTA’s News Sentiment?
      100% of articles about SE:CANTA were positive this week, compared to its sector average of 78%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        ROIVRoivant Sciences
        ILAIsland Pharmaceuticals Ltd
        TLSATiziana Life Sciences
        Showing the stocks with the most bullish news sentiment over the past week